Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Modifying effect of commercially available stannous pyrophosphate (PYRO-Sn) on the tissue affinity of 99mTc pertechnetate

  • 25 Accesses

Abstract

Investigations were performed to examine the conditions required for in vivo labelling of red blood cells (RBCs) with 99mTc after injection of stannous pyrophosphate. It was found that good in vivo labelling of RBCs is possible and that the efficacy of this procedure is high. The highest concentration of 99mTc in the blood occurred in the first 2 h after pertechnetate injection, and the optimum time between stannous pyrophosphate and pertechnetate injection ranged from 10 to 30 min.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Alderson, P.O., Bernier, D.R., Ludbrook, P.A., Harwig, J.F., Roberts, R., Sobel, B.E.: Serial radionuclide determinations of the ejection fraction with 99mTc-labeled red blood cells. Radiology 119, 729–730 (1976)

  2. 2.

    Atkins, H.L., Eckelman, W.C., Klopper, J.F., Richards, P.: Vascular imaging with 99mTc-red blood cells. Radiology 106, 357–360 (1973)

  3. 3.

    Bardy, A., Fonyé, H., Goblin, R., Beydon, J., Tovar, G. de, Pannecière, C., Hégésippe, M.: Techneitum-99m labeling by means of stannous pyrophosphate: Application to bleomycin and red blood cells. J. Nucl. Med. 16, 435–437 (1975)

  4. 4.

    Chandler, W.M., Shuck, L.D.: Abnormal technetium-99m pertechnetate imaging following stannous pyrophosphate bone imaging. J. Nucl. Med. 16, 518 (1975)

  5. 5.

    Fischer, T., Wolf, R., Leon, A.: Technetium-99m as a label for erythrocytes. J. Nucl. Med. 8, 229–232 (1967)

  6. 6.

    Hamilton, R.G., Alderson, P.O.: A comparative evaluation of techniques for rapid and efficient in vivo labeling of red cells with 99mTc pertechnetate. J. Nucl. 18, 1008–1011 (1977)

  7. 7.

    Khentigan, A., Garret, M., Lum, D., Winchell, H.S.: Effects of prior administration of Sn/II/complexes on in vivo distribution of 99mTc-pertechnetate. J. Nucl. Med. 17, 380–384 (1976)

  8. 8.

    McRae, J., Sugar, R.M., Shipley, B., Hook, G.R.: Alterations in tissue distribution of 99mTc-pertechnetate in rats given stannous tin. J. Nucl. Med. 15, 151–155 (1974)

  9. 9.

    Pavel, D.G., Zimmer, A.M., Paterson, V.N.: In vivo labeling of red blood cells with 99mTc: A new approach to blood pool visualization. J. Nucl. Med. 18, 305–308 (1977)

  10. 10.

    Smith, T.D., Richards, P.: A simple kit for the preparation of 99mTc-labeled red blood cells. J. Nucl. Med. 17, 126–132 (1976)

  11. 11.

    Stokelý, E.M., Parkey, R.W., Bonte, F.J., Willerson, J.T.: Gated blood pool imaging following 99mTc stannous pyrophosphate imaging. Radiology 120, 433–434 (1976)

  12. 12.

    Zimmer, A.M.: In vitro technetium-99m red blood cell labeling using commercial stannous pyrophosphate. Am. J. Hosp. Pharm. 34, 264–267 (1977)

Download references

Author information

Correspondence to E. Dziuk.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Baltrukiewicz, Z., Przedlacki, J. & Dziuk, E. Modifying effect of commercially available stannous pyrophosphate (PYRO-Sn) on the tissue affinity of 99mTc pertechnetate. Eur. J. Nucl. Med. 5, 45–47 (1980). https://doi.org/10.1007/BF00261206

Download citation

Keywords

  • Public Health
  • Blood Cell
  • Nuclear Medicine
  • Pyrophosphate
  • Optimum Time